Glooko said this week that it inked an agreement with nonprofit research organization T1D Exchange to use Glooko’s diabetes management solution to incorporate anonymized diabetes data into the TID Exchange Quality Improvement Collaborative (QIC). Mountain View, Calif.-based Glooko said that the QIC is a data platform and learning collaborative made up of 11 U.S. diabetes […]
Senseonics touts strong safety profile in long-term Eversense CGM post-market registry study
Senseonics (NYSE:SENS) said yesterday that is presenting long-term safety data on its Eversense CGM from a European post-market clinical follow up registry later this week, touting that results showed the device as having a strong safety profile. The presentation is slated to take place this Saturday as part of the American Diabetes Association’s Scientific Sessions in […]
Companion Medical, Glooko ink InPen insulin pen data integration deal
Companion Medical said today that it inked a partnership deal with Glooko to integrate data from its InPen smart insulin injection pen into Glooko’s diabetes data management system and mobile application. The integration will be performed through Apple‘s (NSDQ:AAPL) Apple Health application, San Diego-based Companion Medical said, and will allow users to automatically integrate insulin data […]
Blood glucose monitor dev Intuity Medical raises $26m
Blood glucose monitor maker Intuity Medical has raised approximately $26.3 million in a new round of mixed financing, according to a recently posted SEC filing. Fremont, Calif.-based Intuity Medical is developing the Pogo all-in-one automatic blood glucose monitoring system. The Pogo platform incorporates test strips, lancets and a lancing device into a compact meter and cartridge […]
Ocular Therapeutix touts Medicare reimbursement win
Ocular Therapeutix (NSDQ:OCUL) said today that the Centers for Medicare and Medicaid Services approved a transitional pass-through payment status and established a new reimbursement C-code for its Dextenza device. The Bedford, Mass.-based company’s Dextenza device is designed to deliver drugs for up to 30 days following treatment in a physician’s office. Ocular Therapeutix is positioning its […]
Valeritas touts ADA’s inclusion of patch-like insulin delivery devices in diabetes management guidelines
Valeritas (NSDQ:VLRX) said today that the American Diabetes Association has endorsed the use of “disposable patch-like devices” for insulin delivery, which includes its V-Go wearable insulin delivery device. The Bridgewater, N.J.-based company said that the endorsement was made as part of the the ADA’s annual Standards of Medical Care for 2019, published in the journal Diabetes […]
Valeritas board approves 1-for-20 reverse split
Valeritas (NSDQ:VLRX) said today that its board of directors approved a 1-for-20 reverse split of its common stock. Through the move, the Bridgewater, N.J.-based company said that each owner of its common stock will receive a single share for every 20 shares they previously held. Fractional shares as a result of the split will be settled […]
Thermo Fisher to buy Irish drug manufacturing site from GSK for $101m
Thermo Fisher Scientific‘s (NYSE:TMO) said today that it inked a deal to acquire a Cork, Ireland-based drug substance manufacturing site from GlaxoSmithKline (NYSE:GSK) for approximately $100.6 million (EU €90 million). Waltham, Mass.-based Thermo Fisher said that the acquisition of the new site will allow it to expand capacity and meet customer demand for both the development and […]
B. Braun pledges $1B to alleviate IV solution shortages
B. Braun said yesterday that it is investing $1 billion into new and enhanced IV therapy manufacturing facilities to help alleviate saline and other IV fluid shortages faced by healthcare providers in the U.S. The investment, dubbed the ‘Solutions for Life’ initiative, includes a new manufacturing facility in Daytona Beach, Fla. and improvements to existing […]
Valeritas shares fall despite Street-topping Q1 sales
Shares in Valeritas (NSDQ:VLRX) are down more than 15% in after-hours trading despite the medtech firm releasing first quarter 2019 earnings that beat sales expectations and met loss-per-share consensus from Wall Street analysts. The Bridgewater, N.J.-based company posted losses of approximately $14.7 million, or 15¢ per share, on sales of $6.4 million for the three months […]
